q-bio.GNNov 1, 2026

An auditable agentic pipeline for variant-to-gene prioritisation, validated against orthogonal functional evidence

Authors: Shakuntala Baichoo, Sohail, Sarkar, Bo Wang

Organizations: Neel · PMCC AI Lab, University Health Network · Vector Institute

Abstract

Assigning GWAS variants to causal genes requires evidence from multiple resources. We present V2G, an agentic pipeline that records evidence retrieval and returns ranked genes alongside the retrieved evidence. We evaluate whether language-model reranking improves gene prioritisation and whether its gains depend on the retrieved evidence or recall of known associations. On 135 held-out loci where candidate retrieval succeeded and Open Targets L2G predicts, reranking by a language model improves Precision@1 over the evidence ordering it receives, 0.793 against 0.711 (+0.081, 95% CI +0.038 to +0.129), and over nearest-gene assignment (+0.178); no difference from Open Targets L2G or from training-membership baselines was detected. Given only the trait and the candidate gene symbols, in shuffled order, the same model scores 0.864 on these loci (three seeds, 0.859 - 0.867) and names the reference gene at 0.594 of the loci where the pipeline never retrieved it; with each gene's symbol moved to another gene's evidence row it follows the top-scored row and scores 0.284. The gain over the evidence ordering is recall of known genes, and the evidence as presented anchors the model to the ordering rather than informing it. Across the 296 held-out loci (five seeds each) the model keeps the given top candidate at 86% of decisions; at naturally retrieved loci its departures select a reference gene in 85% of departure decisions (31 of 37 loci), and none displaced one. Its calls carry trait-matched mouse mutant or Mendelian phenotype annotations more often than other candidates at the same locus. Train-test overlap is reported throughout. The study includes a frozen benchmark, cached predictions and reproduction code.

Explore similar work

Aug 26, 2026

Homo-RAG: Homology-Guided Retrieval-Augmented Generation for Cross-Species Gene Function Prediction

The functional annotation of genes in non-model organisms remains a significant challenge in computational biology, with 20-70% of sequenced genes lacking characterized functions. Traditional homology-based methods are often costly and strongly dependent on high sequence similarity. This study presents Homo-RAG, a framework for large language model-based gene function prediction that integrates homology-guided multi-hop retrieval with evidence-aware ranking. The framework exploits biological relationships between zebrafish and human orthologs to guide evidence acquisition from ZFIN, UniProt, and PubMed through hybrid dense and lexical retrieval. An Evidence Confidence Score (ECS) integrates semantic relevance, entity matching, orthology information, source reliability, and literature association signals to refine the ranking of retrieved evidence. Extensive evaluation across 150 queries and 7,200 retrieved documents shows that evidence weighting parameter of lambda=0.50 improves NDCG@10 to 0.9879 and MRR to 0.99, while retrieving relevant evidence for 99.33% of queries. Furthermore, 80% of the retrieved documents are query-exclusive, indicating that evidence quality complements rather than replaces retrieval relevance. These findings establish Homo-RAG as a practical and robust framework for reliable, evidence-grounded gene function prediction in understudied organisms. The study addresses important limitations of conventional annotation pipelines while identifying opportunities for future improvements in evidence features and attribution mechanisms.
Oct 8, 2026

Unlocking the Regulatory Genome by ARGUS: An Evidence-Constrained Agentic Framework for Interpreting Single Nucleotide Variants

Over 90% of disease-associated variants from genome-wide association studies fall in noncoding regulatory regions, yet their functional interpretation remains a central open problem in genomic medicine. Large language models prompted to interpret such variants routinely hallucinate transcription factor (TF) binding changes, fabricate experimental support, and assign biological significance to statistically negligible signals. We present ARGUS (Agentic Regulatory Genomics for an Uncertainty-aware Scientist), which strictly separates deterministic biological computation from LLM-mediated reasoning. ARGUS wraps 458 DNABERT-based TF binding models in a hypothesis-directed investigation loop where a planner selects evidence sources based on current uncertainty, a verifier deterministically interprets each observation, and intermediate results change the investigation path. On variant rs6983267 at the 8q24 cancer risk locus, the same planner produces four divergent trajectories for four TFs. FOXA1 is rescued in 3 steps when real ADASTRA allele-specific binding data (15 experiments, FDR = 0.030) reveals a model false negative masked by saturation. KLF6 traverses 8 steps across ADASTRA, JASPAR motif analysis, and ENCODE cCRE regulatory annotation before abstaining due to mixed indirect evidence. RAD21 abstains in 8 steps after ADASTRA returns a coverage-qualified but nonsignificant allelic test (5 experiments, FDR = 0.65), and SP1, which shares FOXA1's saturated retained prediction, abstains because no direct experimental evidence exists at this locus. All observations come from real ADASTRA, JASPAR, and ENCODE cCRE queries; none are simulated. A comparison of fixed-priority and LLM-mediated planning shows that the LLM planner reaches identical verdicts with fewer tool calls by declining evidence that cannot resolve the claim under test.
Mar 20, 2026

G2DR: A Genotype-First Framework for Genetics-Informed Target Prioritization and Drug Repurposing

Human genetics offers a promising route to therapeutic discovery, yet practical frameworks translating genotype-derived signal into ranked target and drug hypotheses remain limited, particularly when matched disease transcriptomics are unavailable. Here we present G2DR, a genotype-first prioritization framework propagating inherited variation through genetically predicted expression, multi-method gene-level testing, pathway enrichment, network context, druggability, and multi-source drug--target evidence integration. In a migraine case study with 733 UK Biobank participants under stratified five-fold cross-validation, we imputed expression across seven transcriptome-weight resources and ranked genes using a reproducibility-aware discovery score from training and validation data, followed by a balanced integrated score for target selection. Discovery-based prioritization generalized to held-out data, achieving gene-level ROC-AUC of 0.775 and PR-AUC of 0.475, while retaining enrichment for curated migraine biology. Mapping prioritized genes to compounds via Open Targets, DGIdb, and ChEMBL yielded drug sets enriched for migraine-linked compounds relative to a global background, though recovery favoured broader mechanism-linked and off-label space over migraine-specific approved therapies. Directionality filtering separated broadly recovered compounds from mechanistically compatible candidates. G2DR is a modular framework for genetics-informed hypothesis generation, not a clinically actionable recommendation system. All outputs require independent experimental, pharmacological, and clinical validation.